^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NI-1801
i
Other names: NI-1801
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Light Chain Biosci
Drug class:
CD47 inhibitor, Mesothelin inhibitor
Related drugs:
over1year
A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers (SITC 2022)
Adverse events are assessed according to CTCAE v5, tumor response is determined according to RECIST 1.1. Key inclusion criteria include (1) histologically or cytologically confirmed diagnosis of epithelial ovarian cancer (high-grade serous or endometroid), triple-negative breast cancer, or non-squamous non-small cell lung cancer, (2) advanced, metastatic, or recurrent disease, and (3) MSLN expression with staining intensity of ≥2+ as per immunohistochemistry in ≥60% of tumor cells.
Clinical • P1 data • IO biomarker
|
MSLN (Mesothelin) • CD47 (CD47 Molecule)
|
MSLN expression • MSLN positive
|
NI-1801
almost2years
A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers (clinicaltrials.gov)
P1, N=40, Recruiting, NovImmune SA
New P1 trial
|
MSLN (Mesothelin)
|
MSLN expression
|
NI-1801
Share via
